ArticleCancers2023

Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.

Takayuki Tokunaga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.